Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Xanthohumol induces paraptosis of leukemia cells through p38 mitogen activated protein kinase signaling pathway.

Mi X, Wang C, Sun C, Chen X, Huo X, Zhang Y, Li G, Xu B, Zhang J, Xie J, Wang Z, Li J.

Oncotarget. 2017 May 9;8(19):31297-31304. doi: 10.18632/oncotarget.16185.

2.

Xanthohumol inhibits proliferation of laryngeal squamous cell carcinoma.

Li Y, Wang K, Yin S, Zheng H, Min D.

Oncol Lett. 2016 Dec;12(6):5289-5294. doi: 10.3892/ol.2016.5313. Epub 2016 Oct 25.

3.

Isoxanthohumol--Biologically active hop flavonoid.

Żołnierczyk AK, Mączka WK, Grabarczyk M, Wińska K, Woźniak E, Anioł M.

Fitoterapia. 2015 Jun;103:71-82. doi: 10.1016/j.fitote.2015.03.007. Epub 2015 Mar 12.

PMID:
25771121
5.

Enhanced T cell lymphoma in NOD.Stat5b transgenic mice is caused by hyperactivation of Stat5b in CD8+ thymocytes.

Chen B, Yi B, Mao R, Liu H, Wang J, Sharma A, Peiper S, Leonard WJ, She JX.

PLoS One. 2013;8(2):e56600. doi: 10.1371/journal.pone.0056600. Epub 2013 Feb 14.

6.

The AKT/NF-κB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration.

Benelli R, Venè R, Ciarlo M, Carlone S, Barbieri O, Ferrari N.

Biochem Pharmacol. 2012 Jun 15;83(12):1634-42. doi: 10.1016/j.bcp.2012.03.006. Epub 2012 Mar 17.

PMID:
22445931
7.

Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia.

Lust S, Vanhoecke B, VAN Gele M, Boelens J, VAN Melckebeke H, Kaileh M, Vanden Berghe W, Haegeman G, Philippé J, Bracke M, Offner F.

Anticancer Res. 2009 Oct;29(10):3797-805.

8.

Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells.

Harikumar KB, Kunnumakkara AB, Ahn KS, Anand P, Krishnan S, Guha S, Aggarwal BB.

Blood. 2009 Feb 26;113(9):2003-13. doi: 10.1182/blood-2008-04-151944. Epub 2008 Oct 24.

9.

Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.

Monteghirfo S, Tosetti F, Ambrosini C, Stigliani S, Pozzi S, Frassoni F, Fassina G, Soverini S, Albini A, Ferrari N.

Mol Cancer Ther. 2008 Sep;7(9):2692-702. doi: 10.1158/1535-7163.MCT-08-0132.

10.

AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies.

Dell'Eva R, Ambrosini C, Vannini N, Piaggio G, Albini A, Ferrari N.

Cancer. 2007 Nov 1;110(9):2007-11.

11.

Synthesis of demethylxanthohumol, a new potent apoptosis-inducing agent from hops.

Diller RA, Riepl HM, Rose O, Frias C, Henze G, Prokop A.

Chem Biodivers. 2005 Oct;2(10):1331-7.

PMID:
17191934
12.

Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism.

Lust S, Vanhoecke B, Janssens A, Philippe J, Bracke M, Offner F.

Mol Nutr Food Res. 2005 Sep;49(9):844-50.

PMID:
16144030

Supplemental Content

Loading ...
Support Center